Inventor · disambiguated record
Vinay K. Jain
Also filed as: JAIN VINAY · JAIN VINAY K · JAIN VINAY KUMAR · JAIN VINAY KUMAR GANESHMAL
44 granted patents·27 pending applications·351 citations·filing 2012–2025
97Inventor score
Files withAROG PHARMACEUTICALS INC36EVONIK OPERATIONS GMBH11VMWARE INC8AROG PHARMACEUTICALS LLC5JOSHI SHRADDHA SANJEEV3
Top patents by PatentIndex Score
71 records- 0198US11316773B2Configuring edge device with multiple routing tablesVMWARE INC·Filed 2020·Granted Apr 26, 2022·14 cites·20 claims
- 0295US12171757B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2022·Granted Dec 24, 2024·1 cites·19 claims
- 0395US10780086B2Method of inhibiting constitutively active phosphorylated FLT3 kinaseAROG PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·6 cites·29 claims
- 0495US10749870B2Adaptive device enrollmentVMWARE INC·Filed 2017·Granted Aug 18, 2020·174 cites·15 claims
- 0595US10213423B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2017·Granted Feb 26, 2019·14 cites·29 claims
- 0695US9393240B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS LLC·Filed 2015·Granted Jul 19, 2016·17 cites·43 claims
- 0794US11743168B2Edge device implementing a logical network that spans across multiple routing tablesVMWARE INC·Filed 2022·Granted Aug 29, 2023·2 cites·18 claims
- 0894US9801870B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2016·Granted Oct 31, 2017·12 cites·43 claims
- 0994US9801869B2Method of inhibiting constitutively active phosphorylated FLT3 kinaseAROG PHARMACEUTICALS INC·Filed 2015·Granted Oct 31, 2017·14 cites·37 claims
- 1094US9101624B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS LLC·Filed 2013·Granted Aug 11, 2015·18 cites·43 claims
- 1192US10835525B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2019·Granted Nov 17, 2020·5 cites·23 claims
- 1292US9480683B2Method of inhibiting mutant C-kitAROG PHARMACEUTICALS LLC·Filed 2013·Granted Nov 1, 2016·17 cites·25 claims
- 1392US9023880B2Method of inhibiting constitutively active phosphorylated FLT3 kinaseAROG PHARMACEUTICALS LLC·Filed 2013·Granted May 5, 2015·14 cites·37 claims
- 1492US2025032475A1Crenolanib for Treating FLT3 Mutated Proliferative DisordersAROG PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1591US11078541B2Crenolanib for treating FLT3 mutated proliferative disorders associated mutationsAROG PHARMACEUTICALS INC·Filed 2017·Granted Aug 3, 2021·3 cites·21 claims
- 1691US9889127B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2016·Granted Feb 13, 2018·9 cites·24 claims
- 1790US11523992B2Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machineEVONIK OPERATIONS GMBH·Filed 2020·Granted Dec 13, 2022·4 cites·14 claims
- 1890US10251877B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2018·Granted Apr 9, 2019·7 cites·24 claims
- 1988US11969420B2Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disordersAROG PHARMACEUTICALS INC·Filed 2021·Granted Apr 30, 2024·1 cites·13 claims
- 2088US11524006B2Crenolanib for treating TRK kinase associated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2021·Granted Dec 13, 2022·1 cites·21 claims
- 2188US11007188B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2019·Granted May 18, 2021·1 cites·28 claims
- 2287US11738017B2Method of inhibiting constitutively active phosphorylated FLT3 kinaseAROG PHARMACEUTICALS INC·Filed 2020·Granted Aug 29, 2023·1 cites·21 claims
- 2387US11458131B2Crenolanib for treating FLT3 mutated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2020·Granted Oct 4, 2022·1 cites·22 claims
- 2486US11642340B2Method of inhibiting mutant C-KITAROG PHARMACEUTICALS INC·Filed 2020·Granted May 9, 2023·1 cites·25 claims
- 2583US2023338360A1Method of Inhibiting Constitutively Active Phosphorylated FLT3 KinaseAROG PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2682US12383549B2Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disordersAROG PHARMACEUTICALS INC·Filed 2024·Granted Aug 12, 2025·0 cites·8 claims
- 2782US12255804B2Edge device implanting a logical network that spans across multiple routing tablesVMware LLC·Filed 2023·Granted Mar 18, 2025·0 cites·18 claims
- 2882US10111838B2Pharmaceutical or nutraceutical composition with resistance against the influence of ethanolEVONIK ROEHM GMBH·Filed 2015·Granted Oct 30, 2018·6 cites·19 claims
- 2980US11980692B2Process for preparing a coated hard shell capsuleEVONIK OPERATIONS GMBH·Filed 2018·Granted May 14, 2024·3 cites·8 claims
- 3080US2025184266A1Edge device implanting a logical network that spans across multiple routing tablesVMware LLC·Filed 2025·Application pending·0 cites
- 3178US11730708B2Dosage form for use in treating or preventing of a diseaseEVONIK OPERATIONS GMBH·Filed 2020·Granted Aug 22, 2023·2 cites·15 claims
- 3277US11602533B2Crenolanib combination therapyAROG PHARMACEUTICALS INC·Filed 2019·Granted Mar 14, 2023·1 cites·34 claims
- 3376US12404555B2Crenolanib for treating FLT3 mutated proliferative disorders associated mutationsAROG PHARMACEUTICALS INC·Filed 2021·Granted Sep 2, 2025·0 cites·5 claims
- 3474US12295948B2Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatmentAROG PHARMACEUTICALS INC·Filed 2023·Granted May 13, 2025·0 cites·5 claims
- 3574US10463658B2Method of inhibiting FLT3 kinaseAROG PHARMACEUTICALS LLC·Filed 2014·Granted Nov 5, 2019·2 cites·17 claims
- 3673US2025345322A1Novel combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disordersAROG PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3772US12486256B2Crystal forms of crenolanib and methods of use thereofAROG PHARMACEUTICALS INC·Filed 2023·Granted Dec 2, 2025·0 cites·7 claims
- 3872US12354711B2Methods and systems for screening and design of corrosion inhibitorsTATA CONSULTANCY SERVICES LTD·Filed 2023·Granted Jul 8, 2025·0 cites·17 claims
- 3972US2023241052A1Method of inhibiting mutant c-kitAROG PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4072US2023181565A1Crenolanib combination therapyAROG PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4171US2023060673A1Crenolanib for treating trk kinase associated proliferative disordersAROG PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4270US11857546B2Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatmentAROG PHARMACEUTICALS INC·Filed 2022·Granted Jan 2, 2024·0 cites·9 claims
- 4370US2023000856A1Novel uses of crenolanibAROG PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4469US11713310B2Crystal forms of crenolanib and methods of use thereofAROG PHARMACEUTICALS INC·Filed 2021·Granted Aug 1, 2023·0 cites·16 claims
- 4567US2023088952A1Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machineEVONIK OPERATIONS GMBH·Filed 2022·Application pending·0 cites
- 4662US2025327191A1Corrossion inhibitor compositionsTATA CONSULTANCY SERVICES LTD·Filed 2025·Application pending·0 cites
- 4761US11471451B2Uses of crenolanibAROG PHARMACEUTICALS INC·Filed 2020·Granted Oct 18, 2022·0 cites·31 claims
- 4860US2025161293A1Crenolanib for treating flt3 mutated proliferative disorders relapsed/refractory to prior treatmentAROG PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4959US10972468B2Adaptive device enrollmentVMWARE INC·Filed 2017·Granted Apr 6, 2021·0 cites·20 claims
- 5058US11595395B2Adaptive device enrollmentVMWARE INC·Filed 2021·Granted Feb 28, 2023·0 cites·20 claims
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Vinay K. Jain files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →